GC Genome Corporation (KOSDAQ:340450)
South Korea · Delayed Price · Currency is KRW 7,400.00
-500.00 (-6.33%)
At close: Mar 23, 2026
GC Genome Revenue
In the year 2025, GC Genome had annual revenue of 31.53B KRW with 21.81% growth. GC Genome had revenue of 8.08B in the quarter ending December 31, 2025, with 10.16% growth.
Revenue
31.53B
Revenue Growth
+21.81%
P/S Ratio
5.55
Revenue / Employee
n/a
Employees
n/a
Market Cap
175.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.53B | 5.65B | 21.81% |
| Dec 31, 2024 | 25.89B | -1.40B | -5.15% |
| Dec 31, 2023 | 27.29B | 3.18B | 13.18% |
| Dec 31, 2022 | 24.11B | 5.62B | 30.36% |
| Dec 31, 2021 | 18.50B | 4.94B | 36.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 4.16T |
| Sam Chun Dang Pharm. | 220.74B |
| Daihan Pharmaceutical | 209.00B |
| ALTEOGEN | 202.18B |
| Macrogen | 179.98B |
| REYON Pharmaceutical | 149.34B |
| SAMSUNG PHARM. Co., LTD. | 44.29B |